Elevance Health, Inc. · NYSE:ELV
Elevance Health — Q1 2024 Earnings Presentation
12 slides from Elevance Health's earnings presentation, Apr 18, 2024
Slide 1: Elevance Health 1Q 2024 Earnings Presentation
Elevance Health 1Q 2024 Earnings Presentation April 18, 2024
Slide 2: Key Highlights
Key Highlights 1 1Q 2024 Results • • Elevance Health delivered a solid start to the year, reflecting disciplined execution of our strategic initiatives across our diversified portfolio of businesses 1Q 2024 adjusted diluted EPS of $10.64 grew 12.5% year-over-year • 1Q 2024 adjusted operating gain of
Slide 3: 1Q 2024 Results
1Q 2024 Results Key Highlights Elevance Health 1Q 2024 1Q 2023 Change (%/bps) • Elevance Health delivered first quarter results slightly ahead of Operating Revenue1 $42.3B $41.9B 0.9% internal expectations • Solid performance in both Health Medical Loss Ratio 85.6% 85.8% (20) bps Benefits and Carelo
Slide 4: Health Benefits 1Q 2024 Results
Health Benefits 1Q 2024 Results Key Highlights • Health Benefits delivered solid results Health Benefits 1Q 2024 1Q 2023 Change (%/bps) • Operating revenue reflects expected attrition in Medicaid membership, mostly offset by Operating Revenue1 $37.3B $37.3B (0.1%) premium rate increases to cover med
Slide 5: Health Services (Carelon) 1Q 2024 Results
Health Services 1Q 2024 Results Key Highlights • Carelon scaling diverse array of businesses Carelon 1Q 2024 1Q 2023 Change (%/bps) • Serves as the enterprise flywheel for growth, integrating physical, behavioral, social and pharmacy Operating Revenue1 $12.1B $11.5B 5.2% services to deliver whole he
Slide 6: Flywheel Supports Sustainable, Long-Term Growth
Flywheel Supports Sustainable, Long-Term Growth Health Benefits Health Services Over 46M medical members balanced Optimize Invest in Integrated portfolio of whole health across commercial, Medicaid and the Core Growth solutions connecting care across Medicare, leveraging the assets and physical, beh
Slide 7: Committed to Strong Growth Over the Long-Term
Committed to Strong Growth Over the Long-Term Health Benefits Carelon3 Elevance Health Upper Single Dividends to Low Double Digit CAGR2 20% Upper Single Digit CAGR2 $156B $138B M&A/ Reinvest Mid Teens in Core CAGR2 Capital 50% Revenue1 $41B Allocation (in Billions) 2022 2027 2022 2027 2022 2027 Targ
Slide 8: Forward-Looking Statements
Forward-Looking Statements This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words su
Slide 9: Non-GAAP Measures and Basis of Presentation
Non-GAAP Measures and Basis of Presentation This document references non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and are not intended to be alternatives to any measure calculated in accordance with GAAP. Re
Slide 10: GAAP Reconciliation — Shareholders' Net Income and Earnings Per Diluted Share
Elevance Health GAAP Reconciliation — Shareholders’ Net Income and Shareholders’ Earnings Per Diluted Share Three Months Ended Mar 31 (In millions, except per share data) 2024 2023 Change Shareholders' net income $2,246 $1,989 12.9% Add / (Subtract): Net losses on financial instruments 161 113 Amort
Slide 11: GAAP Reconciliation — Operating Gain, Operating Expense Ratio, and 2024 Outlook
Elevance Health GAAP Reconciliation — Operating Gain, Operating Expense Ratio, and 2024 Outlook Three Months Ended Mar 31 (In millions) 2024 2023 Change Reportable segments operating gain $3,016 $2,831 6.5% Add / (Subtract): Transaction and integration related costs1 52 26 Litigation expenses1 2 1 B
Slide 12: Elevance Health
nw Elevance Health